Covadonga Pañeda holds a Msc. and Ph.D. in Biochemistry and Molecular Biology from Madrid’s Universidad Autónoma and a Master in Biotech Management by Fundación Genoma España. After 4 years as a postdoc at Scripps Research Institute, La Jolla, CA, she moved to industry where she has accumulated a broad experience in biotech leadership and management. Before joining Altamira in 2022, she spent seven years managing Sylentis’ R&D efforts, two years leading the translational activities of several start-up companies, including Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a neuroimmune biopharmaceutical company.